These disorders are not the focus of this review, however these data are relevant to mGlu5 as a target to treat neurodegenerative diseases as these neuropsychiatric symptoms can overlap with neurodegenerative disorders (Husain, 2017). This evidence concerns the gene GRM5 and neurodegenerative disease.